Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s share price traded down 5.3% during trading on Friday . The stock traded as low as $13.13 and last traded at $13.14. 3,490,392 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 10,592,093 shares. The stock had previously closed at $13.87.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.78.

Teva Pharmaceutical Industries Stock Down 4.1 %

The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. The business’s 50 day moving average price is $13.41 and its 200 day moving average price is $11.15. The firm has a market cap of $14.91 billion, a PE ratio of -28.30, a PEG ratio of 1.61 and a beta of 1.05.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.25. The company had revenue of $4.46 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now directly owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the transaction, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders have sold 390,738 shares of company stock valued at $5,132,766 in the last ninety days. 0.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. increased its stake in Teva Pharmaceutical Industries by 184,642.3% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after acquiring an additional 27,696,340 shares during the last quarter. Sound Shore Management Inc CT acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth $80,791,000. State Street Corp increased its stake in Teva Pharmaceutical Industries by 29.4% during the first quarter. State Street Corp now owns 19,564,828 shares of the company’s stock worth $172,988,000 after acquiring an additional 4,441,883 shares during the last quarter. Exor Capital LLP increased its stake in Teva Pharmaceutical Industries by 30.3% during the fourth quarter. Exor Capital LLP now owns 15,008,389 shares of the company’s stock worth $93,903,000 after acquiring an additional 3,486,202 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in Teva Pharmaceutical Industries by 14.4% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock worth $276,000,000 after acquiring an additional 3,413,100 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.